• Bacterial infections

Avelox Generic Name & Formulations

General Description

Moxifloxacin (as HCl) 400mg; tabs.

Pharmacological Class


How Supplied

Tabs—30; Premixed IV soln—contact supplier


Generic Availability


Avelox Indications


Susceptible infections including acute bacterial sinusitis (ABS), acute bacterial exacerbations of chronic bronchitis (ABECB), community acquired pneumonia, skin and skin structure, complicated intra-abdominal infections, plague. For ABS and ABECB: reserve for those who have no alternative treatment options.

Avelox Dosage and Administration


≥18yrs: 400mg once daily. ABS: treat for 10 days. ABECB: treat for 5 days. Pneumonia: treat for 7–14 days. Skin and skin structure: treat for 7 days, if complicated: 7–21 days. Intra-abdominal: treat for 5–14 days. Plague: treat for 10–14 days; begin as soon as possible after suspected or confirmed exposure. IV formulation may be used if oral route not preferable; administer IV infusion over 60mins, may switch from IV to oral route when clinically indicated.


<18yrs: not established.

Avelox Contraindications

Not Applicable

Avelox Boxed Warnings

Boxed Warning

Serious adverse reactions including tendinitis/tendon rupture, peripheral neuropathy, central nervous system (CNS) effects. Exacerbation of myasthenia gravis.

Avelox Warnings/Precautions


Increased risk of disabling and potentially irreversible adverse reactions (including tendinitis/tendon rupture [esp. in patients >60yrs, or those with kidney, heart or lung transplants], peripheral neuropathy, or CNS/psychiatric effects); discontinue immediately if signs/symptoms occur. CNS disorders (eg, cerebral arteriosclerosis, epilepsy) that increase seizure risk. History of myasthenia gravis; avoid. History of QT prolongation, ventricular arrhythmias, proarrhythmic conditions (eg, bradycardia, acute myocardial ischemia), hypokalemia, or hypomagnesemia; avoid. Do not exceed recommended dose or infusion rate; may increase QT prolongation. Increased risk of aortic aneurysm and dissection (esp. in elderly); reserve use only if no alternatives in patients with history or risk of. Hepatic impairment. Monitor ECG in liver cirrhosis. Discontinue at 1st sign of a skin rash, jaundice, or any other hypersensitivity. Monitor blood glucose in diabetic patients; discontinue if hypoglycemia occurs. Maintain adequate hydration. Avoid excessive sun or UV light. Elderly. Pregnancy. Nursing mothers.

Avelox Pharmacokinetics

See Literature

Avelox Interactions


Avoid drugs that prolong QTc interval (eg, Class IA or Class III antiarrhythmics, cisapride, erythromycin, antipsychotics, tricyclics). Oral forms: take at least 4hrs before or 8hrs after iron, zinc, magnesium, aluminum, sucralfate, didanosine (buffered forms). Increased risk of tendinitis/tendon rupture with corticosteroids. Concomitant antidiabetics may increase blood glucose disturbances. Increased seizure risk with concomitant NSAIDs. Monitor warfarin.

Avelox Adverse Reactions

Adverse Reactions

Nausea, diarrhea, dizziness, headache; tendinitis/tendon rupture, peripheral neuropathy, CNS effects, hypersensitivity reactions, phototoxicity (discontinue if occurs), QT prolongation, C. difficile-associated diarrhea, dysglycemia, aortic aneurysm/dissection.

Avelox Clinical Trials

See Literature

Avelox Note

Not Applicable

Avelox Patient Counseling

See Literature